AURORA: A New Dawn
Genovefa A Papanicolaou, Robin K Avery, Catherine Cordonnier, Rafael F Duarte, Shariq Haider, Johan Maertens, Karl S Peggs, Carlos Solano, Jo-Anne H Young, Martha Fournier, Rose Ann Murray, Jingyang Wu, Tien Bo, Drew J Winston · 2024
Read AURORA: A New Dawn by Genovefa A Papanicolaou, Robin K Avery, Catherine Cordonnier, Rafael F Duarte, Shariq Haider, Johan Maertens, Karl S Peggs, Carlos Solano, Jo-Anne H Young, Martha Fournier, Rose Ann Murray, Jingyang Wu, Tien Bo, Drew J Winston (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11650884.txt.
Description
Genovefa Papanicolaou and co-authors wrote a letter in 2024 about a virus trial. The trial, called AURORA, compared two oral drugs for a virus that plagues transplant patients. It was the first blinded trial of its kind with virus clearance as the main goal. The letter answers points raised by another researcher.
The authors explain why treatment ran a fixed eight weeks rather than stopping at clearance. That fixed span kept the blinded design sound and matched the known course of one drug. They also address dose pauses for low white cell counts and the rise of resistance. The reply clarifies how the trial choices were made.
Catalog record
| CREATOR | Genovefa A Papanicolaou, Robin K Avery, Catherine Cordonnier, Rafael F Duarte, Shariq Haider, Johan Maertens, Karl S Peggs, Carlos Solano, Jo-Anne H Young, Martha Fournier, Rose Ann Murray, Jingyang Wu, Tien Bo, Drew J Winston |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |